查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1400507

全球細胞/基因療法 CDMO 市場（2024 年版）：按類型、應用、適應症、地區和國家、市場考察和預測進行分析（2024-2029 年）

Global Cell and Gene Therapy CDMO Market (2024 Edition): Analysis By Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies), Application (Clinical, Pre-clinical), Indication, By Region, By Country: Market Insights and Forecast (2024-2029)
出版日期: | 出版商: Azoth Analytics | 英文 260 Pages | 訂單完成後即時交付

價格

全球細胞和基因治療 CDMO 市場規模預計將從 2022 年的 25.4 億美元成長，2024-2029 年預測期間複合年成長率為 30.75%。在細胞和基因療法不斷進步的推動下，市場呈現健康成長和不斷成長的需求。由於治療範圍的擴大和有利的法規環境，該市場預計將繼續擴大，因為它在各種疾病的創新治療方法的開發和商業化中發揮關鍵作用。在行業參與者大量投資的推動下，市場預計將出現巨大成長。

全球細胞和基因治療產品線正在不斷擴大，涵蓋癌症、罕見疾病和遺傳性疾病等廣泛的治療領域。隨著越來越多的治療方法通過臨床試驗並走向商業化，對製造、製程開發和擴大規模的 CDMO 服務的需求不斷增加。

全球細胞和基因療法 CDMO 組織正在擴大，這是推動細胞和基因療法在全球範圍內全面擴張的主要因素之一。隨著全球對先進細胞和基因療法的需求增加，CDMO 正在各地積極建立生產設施，以滿足生物技術和製藥公司不斷變化的需求。如今，CDMO已成為藥品生產不可或缺的一部分。在過去的十年中，由於併購環境更加活躍，CDMO 的影響力增加。目前有超過 600 個活躍的受託製造廠商(CDMO) 為本地和國際市場提供服務。 CDMO 提供特定的專業知識，幫助「大型製藥企業」和小型發明家將其產品快速推向市場。

生技藥品的崛起可以從對新生技藥品生產設施進行大量投資的 CDMO 數量看出。這些公司包括勃林格殷格翰（投資8.27億美元）、三星生物製品（投資17億美元）、Lonza（投資9.35億美元）、Fujifilm Diosynth Biotechnologies（投資20億美元）等。

此外，在全球範圍內擴張使 CDMO 能夠滿足當地的監管需求，提供客製化的製造解決方案，並增加需要其服務的客戶的可及性。 CDMO 在全球主要市場的存在使他們能夠提供更具適應性和敏捷性的解決方案。這將加速基因和細胞療法的開發和全球商業化。

限制市場成長的突出因素之一是病毒載體的高製造成本。病毒載體作為將治療基因傳遞至目標細胞的載體，對於基因和細胞療法的發展至關重要。病毒載體的生產是一個複雜的過程，通常需要專門的技術、嚴格的品管標準和專門的設備。

目前有五種類型的病毒載體用於基因治療。 AAV 的市場佔有率最高，其次是慢病毒、腺病毒、單純皰疹病毒和逆轉錄病毒。根據 Roland Berger Insights 的數據，單給藥載體的製造成本可能為 100 萬美元至 200 萬美元，預計每批次為 300 萬美元至 700 萬美元。因此，病毒載體的高製造成本阻礙了細胞和基因療法的廣泛商業化和可用性。

該報告審視了全球細胞和基因治療 CDMO 市場，並提供了包括市場規模和預測、區域和細分分析以及主要趨勢和機會在內的資訊。

目錄

第1章 市集背景

  • 產品範圍和產品前景
  • 執行摘要
  • 調查方法

第2章 戰略建議

第3章全球細胞/基因治療CDMO市場：實績與預測（2019-2029）

  • 宏觀經濟因素對細胞和基因治療CDMO市場的影響分析
  • 細胞/基因治療管線
  • 臨床AAV基因治療
  • 核准/藥物：按治療領域
  • 核准的治療方法，管道
  • 基因治療管線
  • 基因治療的分解
  • 基因治療管道：最常見的目標治療領域
  • 細胞/基因治療的形勢
  • 全球細胞和基因療法 CDMO 市場：儀表板
  • 全球細胞和基因治療 CDMO 市場：市場金額評估（2019-2029）
  • 全球細胞和基因治療 CDMO 市場：最新發展和核准的細胞和基因治療
  • 全球細胞和基因療法 CDMO 市場：近期併購和發展
  • COVID-19 對細胞和基因治療 CDMO 市場的影響
  • 按類型分類的全球細胞和基因治療 CDMO市場區隔
    • 全球細胞和基因療法 CDMO 市場：按類型、概述
    • 全球細胞/基因治療CDMO市場規模：細胞治療（金額）（2019-2029）
    • 全球細胞/基因治療CDMO市場規模：基因治療（金額）（2019-2029）
    • 全球細胞/基因治療CDMO市場規模：基因改造細胞治療（金額）（2019-2029）
  • 全球細胞和基因治療 CDMO市場區隔：按應用
    • 全球細胞/基因療法 CDMO 市場：按應用、概述
    • 全球細胞/基因治療 CDMO 市場規模：臨床（金額）（2019-2029）
    • 全球細胞與基因治療 CDMO 市場規模：臨床前（金額）（2019-2029）
  • 全球細胞和基因治療 CDMO市場區隔：按適應症
    • 全球細胞和基因療法 CDMO 市場：按適應症概述
    • 全球細胞和基因治療 CDMO 市場規模：腫瘤疾病（金額）（2019-2029）
    • 全球細胞/基因治療 CDMO 市場規模：感染疾病（金額）（2019-2029）
    • 全球細胞和基因治療 CDMO 市場規模：神經系統疾病（金額）（2019-2029）
    • 全球細胞/基因治療 CDMO 市場規模：其他適應症（金額）（2019-2029）

第4章全球細胞與基因治療 CDMO 市場：區域分析

  • 研究區域範圍
  • 區域簡介

第5章美洲細胞與基因治療 CDMO 市場：實績與預測（2019-2029）

  • 美洲細胞與基因治療 CDMO 市場：簡介
  • 美洲細胞與基因治療 CDMO 市場：市場金額評估（2019-2029）
  • 美洲細胞與基因療法 CDMO 市場：關鍵促進因素
  • 美洲細胞與基因治療 CDMO 市場：細分分析
  • 按類型分類的美洲細胞和基因治療 CDMO市場區隔
  • 美洲細胞和基因治療 CDMO市場區隔
  • 美洲細胞和基因治療 CDMO市場區隔按適應症細分
  • 按國家/地區分類的美洲細胞和基因治療 CDMO市場區隔
    • 美洲細胞和基因療法 CDMO 市場：按國家/地區、概述
    • 美國細胞/基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）
    • 加拿大細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）
    • 其他美洲細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）

第6章歐洲細胞與基因治療 CDMO 市場：實績與預測（2019-2029）

  • 歐洲細胞和基因治療 CDMO 市場：簡介
  • 歐洲細胞與基因治療 CDMO 市場：市場金額評估（2019-2029）
  • 歐洲細胞與基因療法 CDMO 市場：關鍵促進因素
  • 歐洲細胞與基因治療 CDMO 市場：細分分析
  • 歐洲細胞和基因治療 CDMO市場區隔按類型細分
  • 歐洲細胞和基因治療 CDMO市場區隔：按應用
  • 歐洲細胞和基因治療 CDMO市場區隔：按適應症
  • 按國家/地區分類的歐洲細胞和基因治療 CDMO市場區隔
    • 歐洲細胞和基因治療 CDMO 市場：按國家/地區分類，概述
    • 英國細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）
    • 德國細胞和基因治療CDMO市場：市場規模和複合年成長率（2019-2029）
    • 法國細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）
    • 義大利細胞和基因治療CDMO市場：市場規模和複合年成長率（2019-2029）
    • 其他歐洲細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）

第7章亞太細胞與基因治療 CDMO 市場：實績與預測（2019-2029）

  • 亞太細胞與基因治療 CDMO 市場：簡介
  • 亞太細胞與基因治療 CDMO 市場：市場金額評估（2019-2029）
  • 亞太細胞與基因療法 CDMO 市場：關鍵促進因素
  • 亞太細胞與基因治療 CDMO 市場：細分分析
  • 亞太地區細胞和基因治療 CDMO市場區隔按類型細分
  • 亞太地區細胞和基因治療 CDMO市場區隔
  • 亞太地區細胞和基因治療 CDMO市場區隔
  • 按國家/地區分類的亞太地區細胞和基因治療 CDMO市場區隔
    • 亞太細胞和基因治療 CDMO 市場：按國家/地區分類，概述
    • 中國細胞與基因治療CDMO市場：市場規模及複合年成長率（2019-2029）
    • 日本細胞/基因治療CDMO市場：市場規模與複合年成長率（2019-2029）
    • 韓國細胞和基因治療CDMO市場：市場規模和複合年成長率（2019-2029）
    • 印度細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）
    • 其他亞太細胞和基因治療 CDMO 市場：市場規模和複合年成長率（2019-2029）

第8章中東和非洲細胞和基因治療CDMO市場：實績和預測（2019-2029）

  • 中東和非洲細胞和基因治療 CDMO 市場：簡介
  • 中東和非洲細胞和基因治療 CDMO 市場：市場金額評估（2019-2029）
  • 中東和非洲細胞和基因治療 CDMO 市場：關鍵促進因素
  • 中東和非洲細胞和基因治療 CDMO 市場：細分分析
  • 中東和非洲細胞和基因治療 CDMO市場區隔按類型細分
  • 中東和非洲細胞和基因治療 CDMO市場區隔
  • 中東和非洲細胞和基因治療 CDMO市場區隔

第9章市場動態

  • 評估市場動態對全球細胞和基因治療 CDMO 市場的影響
  • 促進因素
  • 抑制因素
  • 趨勢

第10章產業生態系分析

  • 價值鏈分析
  • 波特五力分析模型

第11章競爭定位

  • 企業產品定位
  • Oxford Biomedica病毒載體產品的競爭定位
  • 市場地位矩陣
  • 細胞和基因治療CDMO市場市場佔有率分析
  • 公司簡介
    • Oxford Biomedica
    • Lonza Group AG
    • Catalent, Inc.
    • Samsung Biologics
    • WuXi Biologics
    • Pfizer CentreOne
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories International, Inc.
    • Novartis AG

Executive Summary

Azoth Analytics has released a research report titled "Global Cell and Gene Therapy CDMO Market (2024 Edition)" which provides a complete analysis of the Global Cell and Gene Therapy CDMO Market industry in terms of market segmentation by Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies), Application (Clinical, Pre-clinical), Indication (Oncology Diseases, Infectious Diseases, Neurological Disorder, Others) for the historical period of 2019-2022, estimates of 2023 and the forecast for 2024-2029.

The Global Cell and Gene Therapy CDMO market valued at USD 2.54 billion in 2022 is expected to grow at a CAGR of 30.75% during the forecast period of 2024-2029. The global Cell and Gene Therapy CDMO market has been experiencing robust growth and escalating demand, propelled by continuous advancements in cell and gene therapies. With a broadening scope of therapeutic areas and a favourable regulatory environment, the global Cell and Gene Therapy CDMO market is poised for sustained expansion as it plays a pivotal role in the development and commercialization of ground-breaking therapies for various diseases. The global Cell and Gene Therapy CDMO market is expected to grow at an extraordinary rate driven by significant investments from industry players.

The global pipeline of cell and gene therapies has been expanding, covering a wide range of therapeutic areas, including oncology, rare diseases, and genetic disorders. As more therapies advance through clinical trials and toward commercialization, the demand for CDMO services for manufacturing, process development, and scale-up increases.

Global CDMO organisations for cell and gene therapy are expanding, and this is one of the main factors propelling the global Cell and Gene Therapy's overall expansion. With the increasing global demand for advanced cell and gene therapies, CDMOs are proactively setting up production facilities in various locations to meet the changing demands of biotechnology and pharmaceutical companies. These days, CDMOs are essential to the manufacturing of pharmaceuticals. Over the past ten years, CDMOs have grown in prominence due to a more dynamic mergers and acquisition landscape. Serving both local and international markets, there are currently over 600 active Contract Development and Manufacturing Organizations (CDMOs). CDMOs provide specific expertise that helps both "Big Pharma" and smaller inventors to launch products sooner.

The rise of biologics is seen by the number of CDMOs making significant investments in brand-new biomanufacturing facilities. These companies include Boehringer Ingelheim (USD827M investment), Samsung Biologics (USD1.7B investment), Lonza (USD935M expansion), and Fujifilm Diosynth Biotechnologies (USD2B investment).

Additionally, by expanding globally, CDMOs can meet regional regulatory needs, provide customised manufacturing solutions, and improve accessibility for customers who need their services. CDMOs can provide more adaptable and responsive solutions by being present in important worldwide markets. This helps to speed up the development and global commercialization of gene and cell therapies.

One prominent factor restraining the growth of the global Cell and Gene Therapy CDMO market is the high cost of producing viral vectors. As carriers of therapeutic genes into target cells, viral vectors are essential to the development of gene and cell therapies. Viral vector production is a complex procedure that frequently involves specialized techniques, stringent quality control standards, and specialized facilities.

There are now five viral vectors in use for gene therapy. AAV have the biggest market share, followed by lentiviruses, adenoviruses, herpes simplex viruses and retroviruses. The vector manufacturing cost for a single dose might be as high as USD 1-2 million, given the expected price of USD 3-7 million per batch, according to Roland Berger Insights. Therefore, the high cost of producing viral vectors hampers cell and gene therapies from being widely commercialised and made accessible, which limits their uptake and hinders the expansion of the Cell and Gene CDMO market.

Scope of the Report

  • The report analyses the Global Cell and Gene Therapy CDMO Market by Value (USD Million).
  • The report presents the analysis of Global Cell and Gene Therapy CDMO Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
  • The report analyses the Global Cell and Gene Therapy CDMO Market by Type (Cell Therapy, Gene Therapy, Gene-modified Cell Therapies).
  • The report analyses the Cell and Gene Therapy CDMO Market by Application (Clinical, Pre-clinical).
  • The report analyses the Cell and Gene Therapy CDMO Market by Indication (Oncology Diseases, Infectious Diseases, Neurological Disorder, Other Indications).
  • The report analyses the Cell and Gene Therapy CDMO Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa).
  • The report analyses the Cell and Gene Therapy CDMO Market by Country (United States, Canada, United Kingdom, Germany, France, Italy, China, Japan, South Korea, India).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis.
  • Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Oxford Biomedica, Lonza Group AG, Catalent, Inc., Samsung Biologics, WuXi Biologics, Pfizer CentreOne, Danaher Corporation, Thermo Fisher Scientific Inc., Charles River Laboratories International, Inc., Novartis AG.

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Strategic Recommendations

3. Global Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 3.1 Impact Analysis of Macro Economic Factors on Cell and Gene Therapy CDMO Market
  • 3.2 Cell and Gene Therapy Pipeline
  • 3.3 Clinical AAV Gene Therapies
  • 3.4 Approvals & Drugs by Therapy Area
  • 3.5 Approved Therapies and Pipeline
  • 3.6 Gene Therapy Pipeline
  • 3.7 Gene Therapy Breakdown
  • 3.8 Gene Therapy Pipeline: Most Commonly Targeted Therapeutic Areas
  • 3.9 Cell and Gene Therapy Landscape
  • 3.10 Global Cell and Gene Therapy CDMO Market: Dashboard
  • 3.11 Global Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million)
  • 3.12 Global Cell and Gene Therapy CDMO Market: Recent Development & Approved Cell and Gene Therapies
  • 3.13 Global Cell and Gene Therapy CDMO Market: Recent M&A and Developments
  • 3.14 Impact of COVID-19 on Cell and Gene Therapy CDMO Market
  • 3.15 Global Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 3.15.1 Global Cell and Gene Therapy CDMO Market, By Type Overview
    • 3.15.2 Global Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.15.3 Global Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.15.4 Global Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.16 Global Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 3.16.1 Global Cell and Gene Therapy CDMO Market, By Application Overview
    • 3.16.2 Global Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.16.3 Global Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 3.17 Global Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 3.17.1 Global Cell and Gene Therapy CDMO Market, By Indication Overview
    • 3.17.2 Global Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.17.3 Global Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.17.4 Global Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 3.17.5 Global Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)

4. Global Cell and Gene Therapy CDMO Market: Regional Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 5.1 Americas Cell and Gene Therapy CDMO Market: Snapshot
  • 5.2 Americas Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 5.3 Americas Cell and Gene Therapy CDMO Market: Key Factors
  • 5.4 Americas Cell and Gene Therapy CDMO Market: Segment Analysis
  • 5.5 Americas Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 5.5.1 Americas Cell and Gene Therapy CDMO Market, By Type Overview
    • 5.5.2 Americas Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.5.3 Americas Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.5.4 Americas Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.6 Americas Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 5.6.1 Americas Cell and Gene Therapy CDMO Market, By Application Overview
    • 5.6.2 Americas Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.6.3 Americas Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.7 Americas Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 5.7.1 Americas Cell and Gene Therapy CDMO Market, By Indication Overview
    • 5.7.2 Americas Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.7.3 Americas Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.7.4 Americas Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 5.7.5 Americas Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • 5.8 Americas Cell and Gene Therapy CDMO Market Segmentation: By Country
    • 5.8.1 Americas Cell and Gene Therapy CDMO Market, By Country Overview
    • 5.8.2 United States Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 5.8.2.1 United States Cell and Gene Therapy CDMO Market, By Type
      • 5.8.2.2 United States Cell and Gene Therapy CDMO Market, By Application
      • 5.8.2.3 United States Cell and Gene Therapy CDMO Market, By Indication
    • 5.8.3 Canada Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 5.8.3.1 Canada Cell and Gene Therapy CDMO Market, By Type
      • 5.8.3.2 Canada Cell and Gene Therapy CDMO Market, By Application
      • 5.8.3.3 Canada Cell and Gene Therapy CDMO Market, By Indication
    • 5.8.4 Rest of Americas Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 5.8.4.1 Rest of Americas Cell and Gene Therapy CDMO Market, By Type
      • 5.8.4.2 Rest of Americas Cell and Gene Therapy CDMO Market, By Application
      • 5.8.4.3 Rest of Americas Cell and Gene Therapy CDMO Market, By Indication

6. Europe Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 6.1 Europe Cell and Gene Therapy CDMO Market: Snapshot
  • 6.2 Europe Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 6.3 Europe Cell and Gene Therapy CDMO Market: Key Factors
  • 6.4 Europe Cell and Gene Therapy CDMO Market: Segment Analysis
  • 6.5 Europe Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 6.5.1 Europe Cell and Gene Therapy CDMO Market, By Type Overview
    • 6.5.2 Europe Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.5.3 Europe Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.5.4 Europe Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.6 Europe Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 6.6.1 Europe Cell and Gene Therapy CDMO Market, By Application Overview
    • 6.6.2 Europe Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.6.3 Europe Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.7 Europe Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 6.7.1 Europe Cell and Gene Therapy CDMO Market, By Indication Overview
    • 6.7.2 Europe Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.7.3 Europe Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.7.4 Europe Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 6.7.5 Europe Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • 6.8 Europe Cell and Gene Therapy CDMO Market Segmentation: By Country
    • 6.8.1 Europe Cell and Gene Therapy CDMO Market, By Country Overview
    • 6.8.2 United Kingdom Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.2.1 United Kingdom Cell and Gene Therapy CDMO Market, By Type
      • 6.8.2.2 United Kingdom Cell and Gene Therapy CDMO Market, By Application
      • 6.8.2.3 United Kingdom Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.3 Germany Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.3.1 Germany Cell and Gene Therapy CDMO Market, By Type
      • 6.8.3.2 Germany Cell and Gene Therapy CDMO Market, By Application
      • 6.8.3.3 Germany Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.4 France Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.4.1 France Cell and Gene Therapy CDMO Market, By Type
      • 6.8.4.2 France Cell and Gene Therapy CDMO Market, By Application
      • 6.8.4.3 France Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.5 Italy Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.5.1 Italy Cell and Gene Therapy CDMO Market, By Type
      • 6.8.5.2 Italy Cell and Gene Therapy CDMO Market, By Application
      • 6.8.5.3 Italy Cell and Gene Therapy CDMO Market, By Indication
    • 6.8.6 Rest of Europe Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 6.8.6.1 Rest of Europe Cell and Gene Therapy CDMO Market, By Type
      • 6.8.6.2 Rest of Europe Cell and Gene Therapy CDMO Market, By Application
      • 6.8.6.3 Rest of Europe Cell and Gene Therapy CDMO Market, By Indication

7. Asia Pacific Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 7.1 Asia Pacific Cell and Gene Therapy CDMO Market: Snapshot
  • 7.2 Asia Pacific Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 7.3 Asia Pacific Cell and Gene Therapy CDMO Market: Key Factors
  • 7.4 Asia Pacific Cell and Gene Therapy CDMO Market: Segment Analysis
  • 7.5 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 7.5.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Type Overview
    • 7.5.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.5.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.5.4 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.6 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 7.6.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Application Overview
    • 7.6.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.7 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 7.7.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Indication Overview
    • 7.7.2 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.7.3 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.7.4 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 7.7.5 Asia Pacific Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • 7.8 Asia Pacific Cell and Gene Therapy CDMO Market Segmentation: By Country
    • 7.8.1 Asia Pacific Cell and Gene Therapy CDMO Market, By Country Overview
    • 7.8.2 China Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.2.1 China Cell and Gene Therapy CDMO Market, By Type
      • 7.8.2.2 China Cell and Gene Therapy CDMO Market, By Application
      • 7.8.2.3 China Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.3 Japan Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.3.1 Japan Cell and Gene Therapy CDMO Market, By Type
      • 7.8.3.2 Japan Cell and Gene Therapy CDMO Market, By Application
      • 7.8.3.3 Japan Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.4 South Korea Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.4.1 South Korea Cell and Gene Therapy CDMO Market, By Type
      • 7.8.4.2 South Korea Cell and Gene Therapy CDMO Market, By Application
      • 7.8.4.3 South Korea Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.5 India Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.5.1 India Cell and Gene Therapy CDMO Market, By Type
      • 7.8.5.2 India Cell and Gene Therapy CDMO Market, By Application
      • 7.8.5.3 India Cell and Gene Therapy CDMO Market, By Indication
    • 7.8.6 Rest of Asia Pacific Cell and Gene Therapy CDMO Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
      • 7.8.7.1 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type
      • 7.8.7.2 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application
      • 7.8.7.3 Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication

8. Middle East & Africa Cell and Gene Therapy CDMO Market: Historic and Forecast (2019-2029)

  • 8.1 Middle East & Africa Cell and Gene Therapy CDMO Market: Snapshot
  • 8.2 Middle East & Africa Cell and Gene Therapy CDMO Market: Market Value Assessment, 2019-2029 (USD Million & CAGR)
  • 8.3 Middle East & Africa Cell and Gene Therapy CDMO Market: Key Factors
  • 8.4 Middle East & Africa Cell and Gene Therapy CDMO Market: Segment Analysis
  • 8.5 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Type
    • 8.5.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Type Overview
    • 8.5.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.5.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.5.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.6 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Application
    • 8.6.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Application Overview
    • 8.6.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.6.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • 8.7 Middle East & Africa Cell and Gene Therapy CDMO Market Segmentation: By Indication
    • 8.7.1 Middle East & Africa Cell and Gene Therapy CDMO Market, By Indication Overview
    • 8.7.2 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.7.3 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.7.4 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
    • 8.7.5 Middle East & Africa Cell and Gene Therapy CDMO Market Size, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact Assessment of Market Dynamics on Global Cell and Gene Therapy CDMO Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Value Chain Analysis
  • 10.2 Porter's Five Forces Model

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Competitive Positioning of Oxford Biomedica's Viral Vector Offering
  • 11.3 Market Position Matrix
  • 11.4 Market Share Analysis of Cell and Gene Therapy CDMO Market
  • 11.5 Company Profiles
    • 11.5.1 Oxford Biomedica
    • 11.5.2 Lonza Group AG
    • 11.5.3 Catalent, Inc.
    • 11.5.4 Samsung Biologics
    • 11.5.5 WuXi Biologics
    • 11.5.6 Pfizer CentreOne
    • 11.5.7 Danaher Corporation
    • 11.5.8 Thermo Fisher Scientific Inc.
    • 11.5.9 Charles River Laboratories International, Inc.
    • 11.5.10 Novartis AG

List of Figures

List of Figures

  • Figure 1: Cell & Gene Therapy Assets in Global Development
  • Figure 2: Genetically Modified Cell Therapy Breakdown
  • Figure 3: CAR-T Breakdown
  • Figure 4: Global Cell and Gene Therapy CDMO Market Size, By Value, 2019-2022 (USD Million)
  • Figure 5: Global Cell and Gene Therapy CDMO Market Size, By Value, 2023-2029 (USD Million)
  • Figure 6: Global Cell and Gene Therapy CDMO Market CAGR (%), By Value, 2019-2022, 2024-2029
  • Figure 7: Global Cell and Gene Therapy CDMO Market Size, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 8: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Cell Therapy, 2019-2029 (USD Million)
  • Figure 9: Global Cell and Gene Therapy CDMO Market Size, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 10: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Gene Therapy, 2019-2029 (USD Million)
  • Figure 11: Global Cell and Gene Therapy CDMO Market Size, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 12: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Gene-modified Cell Therapies, 2019-2029 (USD Million)
  • Figure 13: Global Cell and Gene Therapy CDMO Market Size, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 14: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Clinical, 2019-2029 (USD Million)
  • Figure 15: Global Cell and Gene Therapy CDMO Market Size, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 16: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Pre-clinical, 2019-2029 (USD Million)
  • Figure 17: Global Cell and Gene Therapy CDMO Market Size, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 18: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Oncology Diseases, 2019-2029 (USD Million)
  • Figure 19: Global Cell and Gene Therapy CDMO Market Size, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 20: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Infectious Diseases, 2019-2029 (USD Million)
  • Figure 21: Global Cell and Gene Therapy CDMO Market Size, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 22: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Neurological Disorder, 2019-2029 (USD Million)
  • Figure 23: Global Cell and Gene Therapy CDMO Market Size, Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 24: Global Cell and Gene Therapy CDMO Market Absolute Opportunity, By Other Indications, 2019-2029 (USD Million)
  • Figure 25: Americas Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 26: Americas Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 27: Americas Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 28: Americas Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 29: Americas Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 30: Americas Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 31: Americas Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 32: Americas Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 33: Americas Cell and Gene Therapy CDMO Market, By Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 34: Americas Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 35: Americas Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 36: United States Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 37: United States Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 38: United States Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 39: United States Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 40: United States Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 41: Canada Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 42: Canada Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 43: Canada Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 44: Canada Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 45: Canada Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 46: Rest of Americas Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 47: Rest of Americas Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 48: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 49: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 50: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 51: Europe Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 52: Europe Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 53: Europe Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 54: Europe Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 55: Europe Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 56: Europe Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 57: Europe Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 58: Europe Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 59: Europe Cell and Gene Therapy CDMO Market, Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 60: Europe Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 61: Europe Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 62: United Kingdom Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 63: United Kingdom Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 64: United Kingdom Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 65: United Kingdom Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 66: United Kingdom Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 67: Germany Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 68: Germany Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 69: Germany Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 70: Germany Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 71: Germany Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 72: France Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 73: France Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 74: France Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 75: France Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 76: France Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 77: Italy Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 78: Italy Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 79: Italy Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 80: Italy Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 81: Italy Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 82: Rest of Europe Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 83: Rest of Europe Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 84: Rest of Europe Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 85: Rest of Europe Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 86: Rest of Europe Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 87: Asia Pacific Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 88: Asia Pacific Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 89: Asia Pacific Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 90: Asia Pacific Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 91: Asia Pacific Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapies, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 92: Asia Pacific Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 93: Asia Pacific Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 94: Asia Pacific Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 95: Asia Pacific Cell and Gene Therapy CDMO Market, Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 96: Asia Pacific Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 97: Asia Pacific Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 98: China Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 99: China Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 100: China Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 101: China Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 102: China Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 103: Japan Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 104: Japan Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 105: Japan Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 106: Japan Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 107: Japan Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 108: South Korea Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 109: South Korea Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 110: South Korea Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 111: South Korea Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 112: South Korea Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 113: India Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 114: India Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 115: India Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 116: India Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 117: India Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 118: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Value, 2019-2029 (USD Million & CAGR)
  • Figure 119: Rest of Asia Pacific Cell and Gene Therapy CDMO Market Value, By Application, 2022 (USD Million)
  • Figure 120: Rest of Asia Pacific Cell and Gene Therapy CDMO Market Share, By Type, By Value, 2022 (%)
  • Figure 121: Rest of Asia Pacific Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 122: Rest of Americas Cell and Gene Therapy CDMO Market Share, By Indication, 2022 (%)
  • Figure 123: Middle east & Africa Cell and Gene Therapy CDMO Market Size, By Value, 2019H-2029F (USD Million)
  • Figure 124: Middle east & Africa Cell and Gene Therapy CDMO Market Share, By Application, 2022 (%)
  • Figure 125: Middle east & Africa Cell and Gene Therapy CDMO Market, By Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 126: Middle east & Africa Cell and Gene Therapy CDMO Market, By Gene Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 127: Middle East & Africa Cell and Gene Therapy CDMO Market, By Gene-modified Cell Therapy, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 128: Middle east & Africa Cell and Gene Therapy CDMO Market, By Clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 129: Middle East & Africa Cell and Gene Therapy CDMO Market, By Pre-clinical, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 130: Middle east & Africa Cell and Gene Therapy CDMO Market, By Oncology Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 131: Middle east & Africa Cell and Gene Therapy CDMO Market, Infectious Diseases, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 132: Middle east & Africa Cell and Gene Therapy CDMO Market, By Neurological Disorder, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 133: Middle East & Africa Cell and Gene Therapy CDMO Market, By Other Indications, By Value, 2019H-2029F (USD Million & CAGR)
  • Figure 134: Global Impact of Drivers and Restraints
  • Figure 135: Market Share of Prominent Companies of Cell and Gene Therapy CDMO Market, 2022 (%)
  • Figure 136: Oxford Biomedica Revenues, 2020-2022 (USD Million)
  • Figure 137: Oxford Biomedica, Revenue By Business Segment, 2022 (%)
  • Figure 138: Oxford Biomedica, Revenue By Geographic Segment, 2022 (%)
  • Figure 139: Oxford Biomedica, Largest Shareholders, 2022 (%)
  • Figure 140: Lonza Group AG Revenues, 2020-2022 (USD Million)
  • Figure 141: Lonza Group AG Revenue By Customer Group, 2022 (%)
  • Figure 142: Lonza Group AG, By Infrastructure, 2022
  • Figure 143: Lonza Group AG, CDMO Sales By Customer Location , 2022 (%)
  • Figure 144: Lonza Group AG, CDMO Sales By Customer Type , 2022 (%)
  • Figure 145: Lonza Group AG, Distribution of CDMO Customers By Sales, 2022 (%)
  • Figure 146: Catalent, Inc. Revenues, 2020-2022 (USD Million)
  • Figure 147: Catalent, Inc. Revenue By Business Segment, 2022 (%)
  • Figure 148: Catalent, Inc. Revenue By Geographic Segment, 2022 (%)
  • Figure 149: Samsung Biologics Revenues, 2020-2022 (USD Million)
  • Figure 150: Samsung Biologics Revenue By Business Segment, 2022 (%)
  • Figure 151: Samsung Biologics Revenue By Geographic Segment, 2022 (%)
  • Figure 152: WuXi Biologics Revenues, 2020-2022 (USD Million)
  • Figure 153: WuXi Biologics Revenue By Business Segment, 2022 (%)
  • Figure 154: WuXi Biologics Revenue By Geographic Segment, 2022 (%)
  • Figure 155: Pfizer CentreOne Revenues, 2020-2022 (USD Million)
  • Figure 156: Pfizer CentreOne Revenue By Geographic Segment, 2022 (%)
  • Figure 157: Danaher Corporation Revenues, 2020-2022 (USD Million)
  • Figure 158: Danaher Corporation Revenue, By Business Segments, 2022 (%)
  • Figure 159: Danaher Corporation Revenue, By Geographic Segments, 2022 (%)
  • Figure 160: Thermo Fisher Scientific Inc. Revenues, 2020-2022 (USD Million)
  • Figure 161: Thermo Fisher Scientific Inc. Revenue By Business Segment, 2022 (%)
  • Figure 162: Thermo Fisher Scientific Inc. Revenue By Geographic Segment, 2022 (%)
  • Figure 163: Charles River Laboratories International, Inc. Revenues, 2020-2022 (USD Million)
  • Figure 164: Charles River Laboratories International, Inc. Revenue By Business Segment, 2022 (%)
  • Figure 165: Charles River Laboratories International, Inc. Revenue By Geographic Segment, 2022 (%)
  • Figure 166: Novartis AG Revenues, 2020-2022 (USD Million)
  • Figure 167: Novartis AG Revenue By Business Segment, 2022 (%)
  • Figure 168: Novartis AG Revenue By Geographic Segment, 2022 (%)

List of Tables

Table A1: Global Impact of Macro Economic Factors, By Region

Table A2: OXB's Internal Cell and Gene Therapy Pipeline

Table A3: Clinical AAV Gene Therapies for Genetic Neurological Disorders

Table A4: FDA NME Approvals, 2019-2022

Table A5: Drugs by Therapy Area

Table A6: Approved Gene, Cell, and RNA Therapies Globally, for Clinical Use

Table A7: Pipeline Therapies by Category

Table A8: Approved Gene, Cell, and RNA Therapies Globally, for Clinical Use

Table A9: Number of Therapies from Pre-clinical through Pre-registration

Table A10: Therapies in the Clinic (excludes preclinical development)

Table A11: Cell and Gene Therapy Landscape, by Region

Table A12: Landscape of Key Cell and Gene Therapy Service Providers

Table A13: United States Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A14: United States Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A15: United States Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A16: United States Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A17: United States Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A18: United States Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A19: Canada Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A20: Canada Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A21: Canada Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A22: Canada Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A23: Canada Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A24: Canada Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A25: Rest of Americas Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A26: Rest of Americas Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A27: Rest of Americas Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A28: Rest of Americas Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A29: Rest of Americas Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A30: Rest of Americas Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A31: United Kingdom Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A32: United Kingdom Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A33: United Kingdom Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A34: United Kingdom Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A35: United Kingdom Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A36: United Kingdom Elevated Work Platform (MEWP) Market, By Indication, By Value, 2023-2029 (USD Million)

Table A37: Germany Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A38: Germany Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A39: Germany Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A40: Germany Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A41: Germany Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A42: Germany Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A43: France Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A44: France Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A45: France Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A46: France Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A47: France Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A48: France Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A49: Italy Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A50: Italy Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A51: Italy Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A52: Italy Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A53: Italy Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A54: Italy Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A55: Rest of Europe Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A56: Rest of Europe Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A57: Rest of Europe Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A58: Rest of Europe Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A59: Rest of Europe Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A60: Rest of Europe Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A61: China Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A62: China Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A63: China Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A64: China Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A65: China Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A66: China Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A67: Japan Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A68: Japan Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A69: Japan Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A70: Japan Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A71: Japan Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A72: Japan Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A73: South Korea Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A74: South Korea Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A75: South Korea Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A76: South Korea Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A77: South Korea Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A78: South Korea Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A79: India Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A80: India Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A81: India Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A82: India Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A83: India Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A84: India Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A85: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type, By Value, 2019-2022 (USD Million)

Table A86: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Type, By Value, 2023-2029 (USD Million)

Table A87: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application, By Value, 2019-2022 (USD Million)

Table A88: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Application, By Value, 2023-2029 (USD Million)

Table A89: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication, By Value, 2019-2022 (USD Million)

Table A90: Rest of Asia Pacific Cell and Gene Therapy CDMO Market, By Indication, By Value, 2023-2029 (USD Million)

Table A91: Oxford Biomedica Financials, 2020-2022

Table A92: Lonza Group AG Financials, 2020-2022

Table A93: Catalent, Inc. Financials, 2020-2022

Table A94: Samsung Biologics Financials, 2020-2022

Table A95: WuXi Biologics Financials, 2020-2022

Table A96: Pfizer CentreOne Financials, 2020-2022

Table A97: Danaher Corporation Financials, 2020-2022

Table A98: Thermo Fisher Scientific Inc. Financials, 2020-2022

Table A99: Charles River Laboratories International, Inc. Financials, 2020-2022

Table A100: Novartis AG Financials, 2020-2022